If you have been reading about peptide backbone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
In the Winter of 1869, the Spanish Volunteer Corps of Cuba (Spanish: Cuerpos de Voluntarios de Cuba) compiled a list of Freemasons and other Masons in Cuba. This list was not limited to the revolutionary GOCA Freemasons, it also included members of Colon Freemasonry; the Volunteer Corps and the new Antimasonry movement in Cuba did not distinguish between the two, believing that they were all involved in revolutionary activities. Commander Carlos González Boet rounded-up eighteen people near Santiago de Cuba he suspected of being Freemasons at Fraternidad Lodge No. 1. All through the countryside, he sent men in the middle of the night to kidnap men from their homes, or in the middle of broad daylight on the street. Going into the New Year of 1870, Boet took these men to the San Juan de Wilson sugar mill (Spanish: Ingenio San Juan de Wilson), near El Cobre, where he sentenced them as traitors. On February 13, 14, and 15, 1870, González Boet executed them by gunshot without trial, including the Grand Master of Colon, José Andrés Puente Badell, and Esteban Miniet, the Grand Treasurer of Colon. Other Freemasons were arrested and sent to prison. Commander González Boet was also a Freemason.
US pathology firm CPL-Clinical Pathology Laboratories for $US123.5 million (A$121.5 million). In 2010, Sonic Healthcare acquired Labor Lademannbogen (Hamburg, Germany) and Medhold Group (Antwerp, Belgium), and through the IPN the Prime Health Group. In the US, the company acquired CBLPath (Rye Brook, NY) and Physician's Automated Laboratory (Bakersfield, California).
Sickle cell disease is a group of diseases caused by a mutation in a subunit of hemoglobin, a protein found in red blood cells responsible for transporting oxygen. The most dangerous of the sickle cell diseases is known as sickle cell anemia. Sickle cell anemia is the most common homozygous recessive single gene disorder, meaning the affected individual must carry a mutation in both copies of the affected gene (one inherited from each parent) to experience the disease. Hemoglobin has a complex quaternary structure and is composed of four polypeptide subunits – two A subunits and two B subunits. Patients with sickle cell anemia have a missense or substitution mutation in the gene encoding the hemoglobin B subunit polypeptide chain. A missense mutation means the nucleotide mutation alters the overall codon triplet such that a different amino acid is paired with the new codon. In the case of sickle cell anemia, the most common missense mutation is a single nucleotide mutation from thymine to adenine in the hemoglobin B subunit gene. This changes codon 6 from encoding the amino acid glutamic acid to encoding valine. This change in the primary structure of the hemoglobin B subunit polypeptide chain alters the functionality of the hemoglobin multi-subunit complex in low oxygen conditions. When red blood cells unload oxygen into the tissues of the body, the mutated haemoglobin protein starts to stick together to form a semi-solid structure within the red blood cell.
== See also == Dambu nama – Spiced shredded meat floss from Northern Nigeria Bakkwa – Salty-sweet dried meat product Čvarci – Southeastern European pork rind Dried shredded squid – Seafood product Katsuobushi – Dried, fermented, and smoked skipjack tuna Machaca – Mexican dried meat Pemmican – Food mix with long shelf life, sometimes used as survival food Pulled pork – Pork barbecue dish of the Southern United States Serundeng – Indonesian spiced grated coconut Food portal
Sources: en.wikipedia.org
== Availability and purity == Iodine-125 is commercially available in dilute NaOH solution as 125I-iodide (or the hypohalite sodium hypoiodite, NaIO). The radioactive concentration lies at 4 to 11 GBq/mL and the specific radioactivity is > 75 GBq/μmol (7.5 × 1016 Bq/mol). The chemical and radiochemical purity is high. The radionuclidic purity is also high; some 126I (t1/2 = 12.93 d) is unavoidable due to the neutron capture noted above. The 126I tolerable content (which is set by the unwanted isotope interfering with dose calculations in brachytherapy) lies at about 0.2 atom % (atom fraction) of the total iodine (the rest being 125I).
== History == The use of generative artificial intelligence to create sexually explicit images emerged in 2022 on platforms such as Reddit and 4chan. AI-generated pornography became widespread in the early 2020s following Stability AI's release of Stable Diffusion (SD). This open-source model enables the creation of images from text prompts, utilizing the LAION-5B dataset. Following the model's public release, the volume of both explicit and non-explicit AI-generated media content increased. Due to the open-source nature of Stable Diffusion, there were no restrictions on image generation, which led to controversies regarding open-access AI and its use in generating explicit content. Over time, open-source AI models improved, enabling the creation of highly realistic images and intensifying calls for regulation in this area.
(2026) present new information on growth and development of teeth of Anchitherium, based on the study of their histology. Evidence from the study of tooth enamel of Miocene Anchitherium, indicative of similar life histories of specimens from Germany and Spain ranging from the MN5 to the MN7/8 interval, is presented by Calderón et al. (2026). Sanz-Pérez et al. (2026) report evidence from the study of isotopic composition of tooth enamel of Hipparion from Miocene (Vallesian) localities in Duero and Madrid basins (Spain) indicative of intensification of seasonality in central Iberian Peninsula by MN 10 interval, as well as indicative of consumption of C3 vegetation by the studied equids and their ecological flexibility. Dağ et al. (2026) study the composition of the hipparion assemblage from the Miocene strata from the Yamula Reservoir localities (Turkey), and interpret the studied assemblage as consistent with presence of regionally variable mosaic habitats. Becker et al. (2026) describe hipparion fossil material from the late Pliocene Jradzor section (Armenia) and transfer "Hipparion" longipes and "H." fissurae to the genus Cremohipparion. Evidence indicating that occlusal enamel patterns in cheek teeth of Pleistocene equids from Alaska and Yukon cannot be used to reliably differentiate among tooth morphotypes is presented by Landry et al. (2026). Song et al.
Limited maceration, early pressing, and early racking to limit contact time of the LAB with potential nutrient sources Maintain sulfur dioxide levels to at least 25 ppm of "free" (unbound) SO2, depending on the pH of the wine, this may mean an addition of 50–100 mg/L of SO2 Maintain pH levels below 3.3 Keep the wine cool at temperatures between 10 and 14 °C (50. 0 to 57.2 °F) Filter the wine at bottling with at least a 0.45-micron membrane filter to prevent any bacteria from making it into the bottle In addition, winemakers can use chemical and biological inhibitors such as lysozyme, nisin, dimethyl dicarbonate (Velcorin), and fumaric acid, though some (like Verlcorin) are restricted in winemaking countries outside the United States. Fining agents, such as bentonite, and putting the wine through cold stabilization will also remove potential nutrients for LAB, thus inhibiting malolactic fermentation. Some experimentation with the use of bacteriophages (viruses that infect bacteria) has been conducted to limit malolactic fermentations, but disappointing results in the cheesemaking industry have led to skepticism about the practical use of bacteriophages in winemaking.
This changeover to ESPN was originally to begin with WrestleMania 42 in April 2026, but in August 2025, it was announced the deal had been moved up. NXT's PLEs continued to air on Peacock until March 15, 2026, with Peacock only maintaining the Saturday Night's Main Event (SNME) specials as well as replays of recent episodes of SmackDown until at least 2029 as well as exclusive documentaries; outside the US, SNME streams on YouTube. In January 2026, more countries merged under Netflix, while Sub-Saharan Africa and Japan remained on SuperSport and Abema, respectively. On April 1, 2026, the last four remaining countries that were still on the standalone WWE Network transitioned to Netflix, permanently shutting down the WWE Network after 12 years. After Peacock lost NXT's PLEs in March, one event streamed on YouTube in April before WWE began a new deal with The CW in June in which 20 NXT PLEs would air on The CW's linear channel, and then beginning in August, NXT's events also began simulcasting on ESPN's streaming service. On October 1, Japan merged under Netflix. In addition to ESPN, WWE's events are still made available on traditional PPV outlets in the United States. WWE also partnered with Fandango to broadcast PLEs in select theaters across the United States, beginning with the 2025 SummerSlam, which was initially exclusive to select Regal Cinemas, with events after SummerSlam expanding to other theater chains. In Canada, WWE's PLEs are available through Vu!, Shaw PPV, or SaskTel PPV, and was formerly shown in select locations of the Cineplex Entertainment chain.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.